MUNICH, January 8, 2015—Cardiologists in Germany ranked Bayer the highest among pharmaceutical companies who are active in cardiology, while diabetologists ranked Novo Nordisk, Lilly and Sanofi highest among companies active in diabetes, according to a new survey by Kantar Health, a leading global healthcare consulting firm. Among general practitioners (GP), Berlin-Chemie and Bayer are ranked highest.
The rankings are based on a set of 20 criteria on which physicians were asked to rate each pharmaceutical company. The criteria included:
- Aspects of the products: Product quality, innovative products, etc.
- Economy: Cost/performance ratio, good benefit assessment by the Federal Joint Committee (G-BA), etc.
- Service: Useful information and/or services for patients, useful information on the internet, etc.
- Care: Good sales force, continuity of care, sensitivity to the problems of the doctor, etc.
- Society/politics: Socially responsible role, competence in health policy issues
The survey also asked physicians to identify which of the listed attributes apply to each pharmaceutical company. The three companies with the best overall image among diabetologists – Novo Nordisk, Sanofi and Lilly – are perceived to be very quality-conscious and medically sound. Among GPs, Berlin-Chemie stands out from the other companies as particularly physician-oriented, service-oriented and price-conscious.
The full report “Corporate Image: 2014" is available for purchase. Contact Dr. Katja Zacharias, Senior Consultant, Marketing Insights, at +49 89 56001929 or firstname.lastname@example.org.
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 600+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. Kantar Health is part of Kantar, the data investment management division of WPP. For more information, please visit www.kantarhealth.com.